$4.12-0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $101.9M | $82.1M | +24.04% |
| Profit | -$23.2M | $8M | -390.85% |
| Profit per share | -$0.07 | $0.03 | -333.33% |
| Free Cash Flow | -$37.8M | $22.5M | -267.69% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from MannKind Corporation’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
MannKind Corporation reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From MannKind Corporation's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$101.9M
+24% y/y
-6.9% q/q
Guided
—
No guide given
Actual
-$0.07
Guided
—
No guide given
Actual
-$2.2M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.